Best Neurology Companies in Australia
The 47 best Neurology companies in Australia in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Bionomics.
- Neurology Market Expected to Witness Sustained Growth
Our analysis of 50 Neurology companies
$7.4b in tracked funding; 74% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Neurology companies in Australia
| # | Company | Disclosed funding | Last round | Employees | Founder | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Bionomics Developing therapeutics for cancer and central nervous system disorders using proprietary drug discovery… | $108M | 26 mo ago | 7 | — | — | 436 patents Small-molecule CNS therapeutics for anxiety, pain, and receptor modulation | — |
| 2 | Actinogen Mdical Developer of therapeutics for the treatment of cognitive impairment | $40M | 56 mo ago | — | Steven Gourlay CEO & Managing Director | — | — | 1 award |
| 3 | Seer Cloud-based wearable device for epilepsy diagnosis and management | $34M | 59 mo ago | 328 | Dean Freestone Co-Founder & CEO | 5 signals ▼17% Earnings · M&A | — | — |
| 4 | PYC Therapeutics Developer of the drug for retinal, liver and neuro-degenerative diseases | $30M | 39 mo ago | 25 | Rohan Hockings CEO | 12 signals Leadership · Capital raise | 48 patents Patents concentrated in chemistry & materials | — |
| 5 | Neuren Pharmaceuticals Drugs for brain injury and neurodegenerative disorders. | $29M | 58 mo ago | 15 | Larry Glass CEO | 3 signals ▼40% Earnings | 10 patents Patents concentrated in health & consumer products | — |
| 6 | Epiminder Developer of an implantable device for EEG monitoring | $25M | 53 mo ago | 14 | Rohan Hoare CEO | 6 signals IPO · FDA approval · Earnings | 8 patents Implantable neuro/physiological monitoring devices with wireless data transfer and analysis | — |
| 7 | EMvision Provider of portable electromagnetic microwave imaging solution | $24M | 29 mo ago | — | Scott Kirkland CEO and Managing Director | — | — | — |
| 8 | Arovella Therapeutics Developer of cell therapies to treat cancer and neurological diseases | $23M | 19 mo ago | 44 | — | — | 2 patents Repurposed anti‑platelet drug anagrelide for oncology, targeting thrombocytosis‑driven cancers | — |
| 9 | Alterity Provider of therapies to treat neurodegenerative disease | $20M | 11 mo ago | 11 | David Stamler Chief Executive Officer | — | — | — |
| 10 | Psylo Developer of psychedelic derived therapeutic for mental illness | $14M | 26 mo ago | 24 | Josh Ismin Co-Founder & CEO | — | — | — |
| 11 | Kinoxis Therapeutics Developer of therapies fort treating CNS disorders | $13M | 24 mo ago | 13 | Hugh Alsop Co-Founder & CEO | — | 66 patents Small‑molecule oxytocin receptor agonists for treating social and substance‑use disorders | — |
| 12 | Incannex Company developing proprietary medicinal cannabinoid drugs and psychedelic medicine therapies 40Funding top 34%Growth top 35%Tech top 44%Talent bottom 49% All 6 signals ▾Fundingtop 34% Growthtop 35% Techtop 44% Talentbottom 49% Marketbottom 29% Globalbottom 25% Funding: Raised $12.5M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 40/100 | $12M | 17 mo ago | — | Joel Latham CEO & MD | — | — | — |
| 13 | Cyban Developer of non-invasive continuous tissue oxygen monitoring device | $5M | 50 mo ago | 19 | Barry Dixon Founder | — | — | — |
| 14 | PharmAust Developer of medicines for the treatment of neurodegenerative diseases | $5M | 52 mo ago | 52 | — | — | — | — |
| 15 | Neurizon Therapeutics Developer of therapeutics for neurodegenerative diseases | $4M | 5 mo ago | — | Michael Thurn CEO & Managing Director | — | — | — |
| 16 | Neurotech International Developer of therapeutics for multiple paediatric neurological disorders | $3M | 106 mo ago | 4 | — | 4 signals Capital raise | — | — |
| 17 | Celosia Therapeutics Developer of therapeutics for neurodegenerative diseases | $2M | 44 mo ago | 1 | Lars Ittner Co-Founder | — | 9 patents Protein therapeutics targeting phosphorylated tau and p38γ for neurodegenerative disease treatment | — |
| 18 | Argenica Therapeutics Developer of neuroprotective therapeutics for stroke and neural injuries | $971K | 13 mo ago | — | Liz Dallimore CEO & Managing Director | — | 3 patents Neuroprotective peptide therapeutics for brain injury and neurodegeneration | 2 launchs · 1 partnership |
| 19 | Cortical Dynamics Developing a brain function monitor which acquires EEG data of anesthetized patients | $250K | 77 mo ago | 8 | — | — | 42 patents Non-invasive neuro-monitoring devices for real-time brain activity measurement | 1 award |
Top 12 Neurology companies in Australia
#1
Public · Melbourne, Victoria · founded 1997 · 11 employees$20.3Mraised▾
Provider of therapies to treat neurodegenerative disease. The company's drugs include PBT434 is meant for Parkinsonian disorders and is being evaluated in clinical trials. The drug is a small molecule designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has been shown to reduce abnormal accumulation of α-synuclein and tau proteins in animal models of disease by restoring normal iron balance in the brain.
- Sep 2025Post IPO$13.1M
- Feb 2021Grant (prize money)$495K
- May 2008Post IPO$6.7M
- Post IPO—
#2
Public · Melbourne, Victoria · founded 2000$3.6Mraised▾
Developer of therapeutics for neurodegenerative diseases. The pipeline includes NUZ-001S-Monepante which targets and address the underlying mechanisms of neurodegenerative disease and treat Amyotrophic lateral sclerosis.
- Feb 2026Post IPO$3.6M
#3
Public · Perth, Western Australia · founded 1999 · 44 employees$23Mraised▾
Developer of cell therapies to treat cancer and neurological diseases. The company is focusing on the development of a natural killer T (iNKT) cell therapy platform for the treatment of human diseases. ZolpiMist is a first-in-class oral spray of zolpidem tartrate to treat short-term insomnia. The company is developing other products to treat migraine, headaches, motion sickness, blood cancers, malignant tumors, and drug-resistant epilepsy.
- Jan 2025Post IPO$20M
- Jan 2022Post IPO$3M
#4
Public · Melbourne, Victoria · founded 2015$12.5Mraised▾
Incannex is a clinical stage pharmaceutical company that specializes in the development of medicinal cannabinoid compounds and psychedelic therapies. They have a diversified portfolio of 28 FDA compliant R&D programs and are well positioned as a leader in the development of novel cannabinoid pharmaceuticals and psychedelic therapies.
- Mar 2025Post IPO$12.5M
#5
Public · Thebarton, South Australia · founded 1996 · 7 employees$107.9Mraised▾
Bionomics engage in discovery and development of therapeutics for cancer and diseases of the central nervous system. Has small molecule product development programs in the areas of cancer, anxiety, memory loss and pain. Its oncology approach includes cancer stem cell therapeutics. Its technology platforms include MultiCore, a diversity orientated chemistry platform for the discovery of small molecule drugs; ionX for the identification of drugs targeting ion channels for diseases of the central nervous system; Angene, a drug discovery platform which incorporates a variety of genomics tools to identify and validate novel angiogenesis targets (involved in the formation of new blood vessels); and CSC Rx Discovery, which identifies antibody and small molecule therapeutics that inhibit the growth of cancer stem cells. These platforms drive Bionomics' pipeline and underpin its established business strategy of securing partners for its key compounds.
- May 2024Post IPO$70M
- Feb 2021Post IPO$17.4M
- Sep 2012Post IPO$10.4M
- Sep 2009Post IPO$10.1M
#6
Public · Nedlands, Western Australia · founded 2019$970.9Kraised▾
Developer of neuroprotective therapeutics for stroke and neural injuries. The company's product line include ARG-007 is a cationic and arginine-rich peptide drug administered intravenously. It has the ability to slow the progression of brain injury and preserve brain cells.
- Jun 2025Grant (prize money)$970.9K
#7
Series B · Melbourne, Victoria · founded 2017 · 13 employees$13.4Mraised▾
Kinoxis Therapeutics is involved in the development of a range of therapeutic compounds for treating CNS disorders in collaboration with the University of Sydney. They are more focused on developing antiaddiction drugs, illicit, and prescription drugs. Their lead compound, SOC-1, which is an anti-addiction drug. It mimics the properties of the oxytocin hormone.
- Aug 2024Series B$9.6M
- Sep 2019Grant (prize money)$4.6M
- Feb 2018Series A$3.9M
#8
Public · Brisbane, Queensland · founded 2017$24Mraised▾
EMvision provides portable electromagnetic microwave imaging solution. The company offers a point-of-care, non-invasive, rapid brain scanner for stroke and brain injury diagnosis and monitoring. Their system provides three-dimensional images of biological tissue with microwave tomography.
- Feb 2024Post IPO$10M
- Oct 2022Grant (prize money)$5M
- Jul 2020Post IPO$9M
#9
Seed · Sydney, New South Wales · founded 2021 · 24 employees$14.2Mraised▾
Developer of psychedelic derived therapeutic for mental illness. It provides psychedelics drugs that are improved treatments against selective serotonin reuptake inhibitors (SSRI) medications, allowing patients to recover from severe mental illness like treatment-resistant depression, anxiety, addiction, and others.
- Jun 2024Seed$8M
- Oct 2022Seed$5M
- Oct 2021Seed$1.2M
#10
Public · Nedlands, Western Australia · founded 2001 · 25 employees$30Mraised▾
Developer of the drug for retinal, liver, and neuro-degenerative diseases. The company offers proprietary CPP (Cell-Penetrating Peptides) technology and RNA-based therapeutics for treating retinal diseases, like Retinitis Pigmentosa responsible for childhood blindness. The company also has a pipeline for neurodegenerative disorders and liver disorders.
- May 2023PE$30M
#11
Public · Sydney, New South Wales · founded 1999$40.4Mraised▾
Developer of therapeutics for the treatment of cognitive impairment. The company is focused on developing a treatment for cognitive impairment in chronic neurodegenerative diseases through the inhibition of cortisol production. Its lead product Xanamem is a novel drug for Alzheimer’s disease, which has been specifically designed to block the production of cortisol in the brain.
- Nov 2021Post IPO—
- May 2018Post IPO$7.1M
- Dec 2017Post IPO$5.3M
- Apr 2015Post IPO$8M
#12
Public · Melbourne, Victoria · founded 1993 · 15 employees$29.3Mraised▾
Neuren Pharmaceuticals is a biopharmaceutical company developing drugs for brain injury and neurodegeneration. Product pipeline in phase 2 stage consists of NNZ-2566 in Rett Syndrome, NNZ-2566 in Fragile X Syndrome, NNZ-2566 in Traumatic Brain Injury. Preclinical and phase 1 stage consists of NNZ-2566 Concussion and NNZ-2591 other neurological conditions. The company has operations in New Zealand (Auckland based head office), Australia and the United States, and is listed on the Australian Securities Exchange (ASX: NEU).
- Sep 2021Post IPO$14.5M
- Jun 2017Post IPO$8.7M
- Oct 2013PE$21.5M
- Nov 2010Grant (prize money)$6.2M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Neurology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Neuroscience & Neurotech is moving in Australia
A read on the academic research around Neuroscience & Neurotech — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 969 Australia-affiliated papers.
- University College London388
- UNSW Sydney61
- Monash University59
- Bionics Institute58
- Newcastle University45
- Neuromodulation3→17
- Stimulation10→19
- Brain stimulation4→12
- Neurostimulation6→14
- Optogenetics1→9
- Neuromodulation6→27
- Brain stimulation9→29
- Epilepsy3→23
- Neurostimulation18→30
- Vagus nerve stimulation2→14
- Neurostimulation7→16
- Neuromodulation4→11
- Epilepsy2→9
- Disease6→11
- Transcranial direct-current stimulation2→6
Where neurotech is researched across Australia
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.